FUJIFILM Corporation announced that it is acquiring all the outstanding shares of Irvine Scientific Sales Company, Inc. (ISUS) and IS JAPAN CO.,LTD., (ISJ) leading companies in cell culture media.
In recent years, there has been increased interest in culture media – Culture media contain the nutrients required for the growth and proliferation of cells – and are essential for cell culturing in the R&D and manufacturing of biopharmaceuticals and regenerative medicine products. The quality of the culture medium can influence the quality and efficiency of cell culturing. The market for cell culture media is expanding following the dramatic growth in the demand for biopharmaceuticals centered around antibody drugs and the increasing need for treatments using cells, and its annual growth is expected to be approximately 10% going forward.
ISUS and ISJ are leading companies in cell culture media with a wide range of products including culture media for biopharmaceutical production, in vitro fertilization and cell therapy. The culture media are manufactured at sites that are in compliance with cGMP standards, and are capable of delivering high-quality products in a timely manner. ISUS distributes mainly in the U.S. and Europe, while ISJ distributes mainly in Japan and Asia, providing culture media to pharmaceutical companies, bio-ventures, and academia around the world. To advance its growth strategies in the healthcare area, Fujifilm continues to invest in contract development and manufacturing of biopharmaceuticals and regenerative medicine.
At FUJIFILM Diosynth Biotechnologies (FDB), manufacturing capacity for antibody drugs has been increased. Cellular Dynamics International, Inc. (CDI), a world-class developer and manufacturer of iPS cell technologies and know-how, is now a wholly owned subsidiary, and to enter the cell culture media business, Fujifilm acquired Wako Pure Chemical Industries, Ltd. (Wako Pure Chemical), a leading reagent manufacturer. With acquisition of ISUS and ISJ, Fujifilm will now be able to provide a broad product portfolio from biopharmaceuticals to in vitro fertilization and cell therapy, strengthening its global business. Utilizing its advanced chemical synthesis and design capabilities cultivated in the photographic film business and the cell preparation and culturing technologies of its group companies such as Japan Tissue Engineering Co., Ltd. (J-TEC), CDI and FDB, Fujifilm will accelerate the development of highly competitive cell culture media, supporting the further growth of its cell culture media business.
Further, by combining the Fujifilm Group’s bio-medical-related technologies and products with the cell culture media technologies and products of ISUS and ISJ, the company will maximize the synergies in areas other than the cell culture media business as well. The expected synergies are the further expansion of the contact development and manufacturing business for biopharmaceuticals, the acceleration of research and development in the area of regenerative medicine, and the further expansion of reagent business.